Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Greece

Research and Innovation Action · Running

GENz-trials GENz-trials: Revolutionizing Clinical Trials to Optimize Assessment of Healthcare Innovations

Coordinator
Aristotelio Panepistimio Thessalonikis, Greece
Runs
1 January 2026 to 31 December 2030
Status
Running
EU funding
€7.1m
Total cost
€14.2m
Partners
16 organisations in 8 countries
Type
Research and Innovation Action
Grant agreement
101252995

What the project is doing

In the project's own words, from its summary on CORDIS.

GENz-trials, a private-public funded pan-European consortium, proposes a next-generation clinical trial framework that integrates data science, automation, and simulation technologies to transform how trials are designed, conducted, and evaluated. The strategy builds on three interlinked innovation pillars. i) Automation of critical trial workflows using generative AI for personalized informed consent, protocol drafting, monitoring, and regulatory submission, thereby reducing administrative burden and expediting trial initiation. ii) Artificial Intelligence (AI)-driven patient recruitment by analysing large-scale Electronic Health Records (EHRs), and real-world datasets to optimize matching between patients and trial protocols, improving enrolment rates, inclusiveness, and avoidance of patient dropout. iii) integration of Digital Twins (DTs) and Synthetic Control Arms (SCAs) for protocol optimization through in-silico simulation and enabling ethically sound alternatives to placebo groups, using real-world data to construct robust comparators with fewer enrolled participants.

GENz-trials will serve as a platform for boosting innovation in the assessment of the added value of integrated healthcare solutions, providing a flexible and data-rich environment to evaluate not only pharmaceuticals, but also diagnostics, digital health tools, and therapeutic combinations, ultimately strengthening health technology assessment, regulatory decision-making, and reimbursement strategies. The GENz-trials framework will be unfolded in three phases: development of core tools; retrospective emulation of historical trials; and prospective validation through a Phase IV clinical equivalence trial comparing a generic anticoagulant with its branded counterpart.

Through this phased strategy, GENz-trials aims to establish a more ethical, inclusive, and cost-effective paradigm for clinical research, accelerating the evaluation and deployment of life-saving healthcare innovations.

Who is involved

OrganisationCityCountryRole
Aristotelio Panepistimio ThessalonikisThessalonikiGreeceCoordinator
Ainigma TechnologiesLeuvenBelgiumParticipant
HictGentBelgiumParticipant
Katholieke Universiteit LeuvenLeuvenBelgiumParticipant
Etos Ligal Salyushans LlcSofiaBulgariaParticipant
Nova Dimension EoodSandanskiBulgariaParticipant
Ubitech LimitedLimassolCyprusParticipant
Daiichi Sankyo Europe GmbHMunichGermanyParticipant
Elpen Pharmaceutical Co IncPikermiGreeceParticipant
Ethniko Kentro Erevnas Kai Technologikis AnaptyxisThermi ThessalonikiGreeceParticipant
Innovation, Information, Intelligence Evolution IkeAthinaGreeceParticipant
Iqvia Hellas Technology Solutions Single Member Societe AnonymeAthensGreeceParticipant
Vianex A.e. Anonymos Emporoviomichaniki Touristiki Xenodocheiaki Kai Naftiliaki Anonymos EtaireiaKifisiaGreeceParticipant
Ecrin European Clinical Research Infrastructure NetworkParisFranceParticipant
Fondazione Policlinico Universitario Agostino Gemelli IrccsRomaItalyParticipant
Fwdfaster Ai Research BVUtrechtNetherlandsParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI